AVXL

San Diego, California--(Newsfile Corp. - October 16, 2026) - Shareholder rights law firm Robbins LLP reminds investors that a class action was filed on behalf of persons and entities who purchased or otherwise acquired Anavex Life Sciences Corp. (NASDAQ: AVXL) securities between November 26, 2025 and August 28, 2026, inclusive (the "Class Period"). Anavex describes itself as "a publicly traded biopharmaceutical company dedicated to the development of novel therapeutics for the treatment of neurodegenerative, neurodevelopmental, and neuropsychiatric disorders.

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Anavex To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Anavex between November 26, 2025 and August 28, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - October 16, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ: AVXL) and reminds investors of the November 30, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

New York, New York--(Newsfile Corp. - October 16, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ: AVXL) on behalf of investors that purchased or otherwise acquired Anavex securities between November 26, 2025 and August 28, 2026 (the "Class Period"). CLICK HERE TO JOIN THE CASE If you are an investor in Anavex and have suffered losses, you may CLICK HERE to contact us.

Anavex now has open INDs in all three core indications: Alzheimer's disease, Rett syndrome, and Fragile X syndrome Phase 2a study will evaluate the safety, tolerability and pharmacokinetics of blarcamesine oral solution in adult males with Fragile X syndrome NEW YORK, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative treatments for central nervous system diseases with significant unmet medical needs, today announced that it has received notification from the U.S. Food and Drug Administration (FDA) that the Company may proceed with its planned clinical study under its Investigational New Drug Application (IND) for ANAVEX®2-73 (blarcamesine) for Fragile X syndrome (FXS), a genetic condition that is the most common inherited cause of intellectual disability and developmental delay and the most commonly known single-gene cause of autism, for which no FDA-approved treatment currently exists. The IND is now open, enabling clinical investigation of blarcamesine in FXS in the United States.

NEW YORK, Oct. 15, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Anavex Life Sciences Corp. (NASDAQ: AVXL) between November 26, 2025 and August 28, 2026, both dates inclusive (the "Class Period"), of the important November 30, 2026 lead plaintiff deadline in the securities class action first filed by the Firm. So what: If you purchased Anavex Life Sciences securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

New York, New York--(Newsfile Corp. - October 15, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Anavex Life Sciences Corp. (NASDAQ: AVXL) and certain of its officers. This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Anavex securities between November 26, 2025 and August 28, 2026, both dates inclusive (the "Class Period").

NEW YORK, Oct. 15, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ: AVXL). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Anavex To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Anavex between November 26, 2025 and August 28, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - October 14, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ: AVXL) and reminds investors of the November 30, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

NEW YORK, Oct. 14, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Anavex Life Sciences Corp. (NASDAQ: AVXL) between November 26, 2025 and August 28, 2026, both dates inclusive (the “Class Period”), of the important November 30, 2026 lead plaintiff deadline in the securities class action first filed by the Firm.

NEW YORK, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Anavex Life Sciences Corp. (“Anavex” or the “Company”) (NASDAQ: AVXL).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.